Laurus Labs Reports Q1 FY27 Results: Revenue Reaches ₹2,026 Cr; EBITDA Improves 66% Year-on-Year

Laurus Labs Reports Q1 FY27 Results: Revenue Reaches ₹2,026 Cr; EBITDA Improves 66% Year-on-Year​

Hyderabad: Laurus Labs Ltd., a pharmaceutical and biotech company focusing on research and development, announced its Unaudited Financial Results for the first quarter of FY27 (Q1 FY27) ended June 30, 2026. The company reported strong financial performance, with revenue climbing to ₹2,026 crore and EBITDA reaching ₹644 crore.

The results show a significant jump in profitability across key metrics, driven by enhanced commercial delivery and operational efficiencies within its business segments.

Financial Highlights for Q1 FY27​

Laurus Labs demonstrated sustained growth over the previous year. The company's financial performance for Q1 FY27 compared to Q1 FY26 is detailed below:

Executive Commentary and Operational Strength​

Dr. Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, commented on the results, noting that the company delivered record quarterly revenue with expanded profitability. This growth was attributed to expanding commercial deliveries within the CDMO sector and consistent strength in its Affordable Medicines portfolio.

Mr. V V Ravi Kumar, Executive Director and Chief Financial Officer, provided insights into the operating performance. He stated that the strong Q1 results were achieved despite challenging macroeconomic volatility. The EBITDA margin at 31.8% reflected improved capacity utilization and operational leverage. Gross margins also saw an expansion of over 3 percentage points to 62.7%, which he attributed to a favorable segment mix.

Dr. Chava highlighted important milestones for the company, including an agreement to in-license two Antibody Drug Conjugates (ADCs) and securing final handover of a new land parcel, reinforcing the long-term growth strategy.

Divisional Performance Overview​

The total revenue of ₹2,026 crore was derived from diversified performance across several business segments:


The division reported the following revenue breakdown:

Segment-Specific Highlights and R&D Focus​

CDMO and Small Molecules: The CDMO segment, which also includes small molecules, reported a revenue of ₹835 crore in Q1 FY27, marking a 69% increase. This growth is primarily driven by late-stage clinical and commercial API supplies, along with the ramp-up of growth projects. The company continued its focus on new modalities and has over 125 active projects across Human health, Animal health, and Crop science.

Bio (Large Molecules): The Bio business contributed ₹35 crore in Q1 FY27, a 21% increase. The division is focusing on enzymatic technology application for small molecule clinical and commercial API projects, with the fermentation facility expected to be commissioned by Q3 FY27.

Affordable Medicines (Generics): This division generated revenue of ₹1,156 crore, reflecting a 10% growth. Growth in this sector was steady, driven by established product volume increases, new launches in the US, and consistent ARV deliveries. Furthermore, the company reported that 92 DMFs have been filed cumulatively, and two product dossiers were filed for developed markets during Q1 FY27.

R&D Investments: Total R&D investments, including CAPEX R&D, stood at ₹118 crore for the quarter, which is 5.8% of revenue and represents a significant 74% year-on-year increase. This investment is dedicated to developing Advanced Biologics infrastructure in areas like Gene Therapy and Antibody Drug Conjugates (ADCs).

In terms of quality metrics, Laurus Labs completed 24 Quality audits in Q1, successfully passing all inspections without critical findings. The company also received approval for its near-term science-based emissions reduction targets from the Science Based Targets initiative (SBTi).

LAURUSLABS Stock Price Movement​

Shares of Laurus Labs Limited are rallying robustly, reaching ₹1598.90 as of 3:10 PM, after gaining 1.95% in live trading. The equity is maintaining extremely strong upward momentum, hitting a prominent 52-week high while logging a considerable volume of approximately 1.77 million shares.